 |
71 Diseases |  |
132 Trials |
|
132 Trials |  |
3143 News |  |
| 12345678910111213...4344» |
- || Halaven (eribulin mesylate) / Eisai
P2 data, Journal: A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE). (Pubmed Central) - Jan 2, 2026
Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity.
- | Review, Journal: The Role of Natural Product Chemistry in Drug Discovery: Two Decades of Progress and Perspectives. (Pubmed Central) - Dec 26, 2025
While growth is modest, NPs remain highly valuable active pharmaceutical ingredients (APIs) with substantial clinical impact. Significant opportunities persist for drug-focused NP R&D efforts, as many recently validated therapeutic targets remain underexplored for NP-D chemotypes.
- | Journal: Monitoring of occupational exposure to hazardous medicinal products in robotic compounding. (Pubmed Central) - Dec 23, 2025
Occupational exposure to HMPs remains consistently below 0.1 ng/cm2, a threshold deemed safe according to various studies. These findings assure the safety of compounding personnel and other hospital staff involved in cancer treatment.
- || Halaven (eribulin mesylate) / Eisai, farletuzumab ecteribulin (MORAb-202) / Eisai
P1 data, Journal, Platinum resistant: Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum-resistant ovarian cancer: Phase I expansion results. (Pubmed Central) - Dec 23, 2025
P1
These findings assure the safety of compounding personnel and other hospital staff involved in cancer treatment. FZEC showed promising antitumor activity, and the observed adverse events were generally manageable, with the exception of ILD, in patients with PROC.
- | Journal: Eribulin and sintilimab combined with radiotherapy in a heavily pretreated patient with advanced retroperitoneal myxoid pleomorphic liposarcoma: a case report and literature review. (Pubmed Central) - Dec 22, 2025
Following this, she received gemcitabine plus albumin paclitaxel as second-line therapy...The demonstrated effectiveness of this multidisciplinary approach underscores its potential as a novel treatment strategy for patients with advanced MPLPS. To our knowledge, this article represents the first detailed documentation of multidisciplinary diagnosis and treatment of MPLPS.
- | Halaven (eribulin mesylate) / Eisai, Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) - Dec 16, 2025
P2, N=37, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
To our knowledge, this article represents the first detailed documentation of multidisciplinary diagnosis and treatment of MPLPS. Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
- | Halaven (eribulin mesylate) / Eisai
Journal: Combining anti-metabolic treatments with the repurposing of eribulin for glioblastoma: a clinical opportunity? (Pubmed Central) - Dec 11, 2025
Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027 No abstract available
- | Halaven (eribulin mesylate) / Eisai
Review, Journal: Epithelial-mesenchymal dynamics in cancer: Role of signalling pathways, stromal interactions and natural therapies. (Pubmed Central) - Dec 1, 2025
Furthermore, marine-based compounds, including caprolactin C, laminaran sulfate, BFP-3, bryostatin 1, sinulariolide, manzamines, halichondrin B, eribulin and biemamides, exhibit significant anti-metastatic effects by targeting EMT-associated pathways. The diverse range of therapeutic molecules discussed in this review provides promising therapeutic avenues for developing targeted strategies against EMT in cancer.
- || Halaven (eribulin mesylate) / Eisai
P2 data, Journal: A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701). (Pubmed Central) - Nov 30, 2025
This phase II study of eribulin for patients with BRAF V600E mutant mCRC did not meet the primary endpoint. Although BM2 on gene expression analysis of BM subtype may be a predictive marker of eribulin efficacy, further studies are required to validate this hypothesis.
- | Biomarker, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Pathological complete response to pembrolizumab in recurrent retroperitoneal dedifferentiated liposarcoma with high tumor mutational burden: a case report. (Pubmed Central) - Nov 29, 2025
This is the first reported case of recurrent retroperitoneal DDLPS with high TMB achieving pCR to pembrolizumab. High TMB and high TAM density in the tumor microenvironment may be predictive biomarkers for the response to ICIs in DDLPS.
- | Halaven (eribulin mesylate) / Eisai
Journal: Improved biodistribution and antitumor effects of a Nectin4 and Trop2 bispecific fatty acid-modified nanobody conjugate. (Pubmed Central) - Nov 27, 2025
In nonclinical evaluations, Eribulin-loaded dtNDC demonstrated potent antitumor efficacy across three xenograft models...These findings position dtNDC as a promising therapeutic combining durable tumor regression with exceptional tolerability. Moreover, its simplified structure and cost-effective manufacturing process make this dtNDC a compelling next-generation therapeutic for cancers.
- |||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trial primary completion date: DESTINY Breast Respond HER2-low Europe (clinicaltrials.gov) - Nov 18, 2025
P=N/A, N=1155, Recruiting, Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Moreover, its simplified structure and cost-effective manufacturing process make this dtNDC a compelling next-generation therapeutic for cancers. Trial primary completion date: Jun 2027 --> Sep 2028
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Halaven (eribulin mesylate) / Eisai
Journal: Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer. (Pubmed Central) - Nov 12, 2025
Outcomes of post-T-DXd treatments differ significantly by MBC subtype and type of regimen administered. The use of SG immediately after T-DXd was associated with relatively short rwPFS across subtypes, highlighting some degree of cross-resistance with T-DXd.
- | Halaven (eribulin mesylate) / Eisai
Phase classification: A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Nov 11, 2025
P1, N=48, Recruiting, Sponsor: M.D. Anderson Cancer Center
The use of SG immediately after T-DXd was associated with relatively short rwPFS across subtypes, highlighting some degree of cross-resistance with T-DXd. Phase classification: P1/2 --> P1
- pumitamig (BNT327) / BioNTech, BMS
Preliminary data from a global multicohort Phase2 randomized trial of pumitamig (PD-L1 (Exhibit Hall) - Nov 10, 2025 - Abstract #SABCS2025SABCS_2447;
P2, P3
The efficacy is particularly clinically meaningful in pts with CPS <10, addressing a critical unmet need. No new safety signals were seen compared to previously characterized safety profile of pumitamig.
- Datroway (datopotamab deruxtecan-dlnk) / Daiichi Sankyo, AstraZeneca
Economic Impact of Adverse Event Management in HR+/HER2? Metastatic Breast Cancer: A Comparative Analysis of Datopotamab deruxtecan and standard of care in the Brazilian Private Healthcare System (Exhibit Hall) - Nov 10, 2025 - Abstract #SABCS2025SABCS_2420;
Dato-DXd demonstrated lower expenditures associated with adverse event management compared to its respective ICC arm comparator. SG was associated with higher AE-related costs relative to its respective ICC arm comparator.
- Chronification of metastatic leiomyosarcoma in 9 lines of therapy by precision oncology: A case report (X / Y (Confex)) - Nov 5, 2025 - Abstract #DGHO2025DGHO_1259;
The identified HRR deficiency enabled targeted PARP inhibition with clinically meaningful disease control. The combination of olaparib and temozolomide may represent a promising treatment option not only in uterine LMS, but also in non-uterine LMS with HRR deficiency.
- Halaven (eribulin mesylate) / Eisai
Efficacy and Safety of Eribulin in Liposarcoma and Leiomyosarcoma: A Systematic Review and Meta-Analysis (X / Y (Confex)) - Nov 5, 2025 - Abstract #DGHO2025DGHO_488;
The combination of olaparib and temozolomide may represent a promising treatment option not only in uterine LMS, but also in non-uterine LMS with HRR deficiency. Eribulin improves survival in liposarcoma and leiomyosarcoma with a manageable safety profile, highlighting its value as an effective treatment and the need for further research to optimize its clinical use
- || Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal: An open-label phase II study: The efficiency and safety of anlotinib?+?eribulin in patients with HER2-negative metastatic breast cancer. (Pubmed Central) - Nov 5, 2025
P2
The most common treatment-related adverse events (TRAEs) were neutropenia (67.14%) and leukopenia (68.57%), with 41.43% and 27.14% of patients experiencing grade 3/4 hematologic toxicities, respectively. These findings suggest that the combination of eribulin and anlotinib demonstrated encouraging efficacy and a manageable safety profile, offering a potential therapeutic option for patients with HER2-negative mBC.
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Halaven (eribulin mesylate) / Eisai, doxorubicin hydrochloride / Generic mfg.
Journal: Targeting Interleukin-6 as a Novel Strategy to Overcome Eribulin Resistance in Breast Cancer. (Pubmed Central) - Nov 5, 2025
These findings suggest that the combination of eribulin and anlotinib demonstrated encouraging efficacy and a manageable safety profile, offering a potential therapeutic option for patients with HER2-negative mBC. These findings suggest that IL-6 contributes to eribulin resistance in breast cancer and that IL-6 receptor inhibition is a promising therapeutic strategy to overcome this resistance.
- |||| Datroway (datopotamab deruxtecan-dlnk) / Daiichi Sankyo, AstraZeneca
Trial primary completion date: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) (clinicaltrials.gov) - Nov 4, 2025
P3, N=644, Active, not recruiting, Sponsor: AstraZeneca
These findings suggest that IL-6 contributes to eribulin resistance in breast cancer and that IL-6 receptor inhibition is a promising therapeutic strategy to overcome this resistance. Trial primary completion date: Dec 2025 --> Aug 2025
- | Halaven (eribulin mesylate) / Eisai
Journal: Prognostic significance of baseline skeletal muscle index and its dynamics in patients with metastatic breast cancer undergoing eribulin treatment. (Pubmed Central) - Nov 3, 2025
Furthermore, on-treatment SMI gain, but not PNI increase, was associated with improved survival. Monitoring and enhancing skeletal muscle mass may improve outcomes, highlighting the importance of integrating supportive care strategies during chemotherapy.
- || Halaven (eribulin mesylate) / Eisai
P4 data, Retrospective data, Journal: Prognosis of Invasive Lobular Carcinoma and Effectiveness of Eribulin in Clinical Practice: A Post Hoc Analysis of a 2-Year Post-Marketing Surveillance. (Pubmed Central) - Nov 3, 2025
P=N/A
Monitoring and enhancing skeletal muscle mass may improve outcomes, highlighting the importance of integrating supportive care strategies during chemotherapy. OS and TTF after eribulin initiation were similar between ILC and IDC cases, suggesting that eribulin might be a beneficial treatment option for ILC.
- | Halaven (eribulin mesylate) / Eisai
New P4 trial: Efficacy and Safety of Epalolitovorellizumab in Combination with Eribulin as Second-line and Later-line Therapy for Patients with Advanced Triple-negative Breast Cancer (EUDRACT) - Oct 31, 2025
P4, N=49, Not yet recruiting, Sponsor: Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital
- pumitamig (BNT327) / BioNTech, BMS
A global Phase III, randomized, double-blind trial of BNT327 plus chemotherapy (chemo) vs placebo plus chemo in patients (pts) with previously untreated locally recurrent inoperable or metastatic, PD-L1 negative triple negative breast cancer (TNBC) (ROSETTA Breast-01) (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_2181;
P1/2
OS and TTF after eribulin initiation were similar between ILC and IDC cases, suggesting that eribulin might be a beneficial treatment option for ILC. Pts are stratified by prior treatment with cancer immunotherapy in the neoadjuvant/adjuvant setting, on-trial chemo regimen, and geography, and randomized 1:1 to receive a combination treatment with BNT327 or placebo plus physician
- Xtandi (enzalutamide) / Pfizer, Astellas, Mifeprex (mifepristone) / Danco Laboratories
Tbcrc 058: a randomized phase 2 study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (nct06099769) (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_2167;
P2
As of 7/9/2025, 19 of 201 pts have begun protocol-specified tx. This trial is supported by the Translational Breast Cancer Research Consortium, The Breast Cancer Research Foundation, The TaTa Sisterhood Foundation, Pfizer/Astellas, and Corcept Therapeutics.
- evexomostat (SDX-7320) / SynDevRx, Halaven (eribulin mesylate) / Eisai
Aretha trial: Safety run-in results of eribulin + evexomostat in metastatic triple-negative breast cancer with metabolic dysfunction (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1991;
P2
Evexomostat + eribulin safety was confirmed and the trial advanced to the randomization phase including a placebo-controlled arm with eribulin. Preliminary biomarker results indicate that insulin resistance was unchanged, and favorable changes were seen in other metabolic markers.
- Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Jbcrg-m06/emerald post-hoc analysis by physician's choice of docetaxel or paclitaxel: efficacy and safety of eribulin mesylate vs taxanes combined with trastuzumab and pertuzumab as first-line for her2-positive locally advanced or metastatic breast cancer (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1945;
P3
No differences in efficacy (i.e. non-inferiority results) were observed based on type of T used. While AEs were generally similar between the E and T groups, regardless of type of T used, a higher incidence of peripheral sensory neuropathy was noted with PTX compared with E or DTX.
- Cytokine score based on expression levels of multiple cytokines is a prognostic indicator in metastatic breast cancer patients treated with chemotherapy (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1582;
The cytokine score, based on the number of elevated cytokines, is an important prognostic indicator for both OS and PFS. Furthermore, since a high cytokine score was associated with higher levels of MDSCs, and lower levels of CD4+ and CD8+ lymphocytes, the cytokine score might be associated with patient outcomes through immune reaction.
- Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
The Utility of MT1-MMP in Predicting Treatment Efficacy with HER2-positive advanced or metastatic breast cancer: JBCRG-M06/EMERALD trial TR (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1580;
The MT1-MMP score is unable to distinguish the combined trastuzumab and pertuzumab with eribulin mesylate or trastuzumab and pertuzumab with taxane therapy. However, it may be a prognostic factor for HER2-positive local advanced or metastatic breast cancer patients treated with the trastuzumab and pertuzumab combination and eribulin mesylate or taxane.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
A comparative study of trastuzumab and pertuzumab combination subcutaneous and intravenous infusion in patients with HER2-positive breast cancer: a retrospective and prospective combined study of time efficiency, cost-effectiveness, quality of life, and socioeconomic impact (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1477;
When combined with eribulin, the median was 198.0 minutes (95% CI 160.8-266.2) in the IV group and 107.0 minutes (95% CI 83.6-164.7) in the SC group... The SC formulation of trastuzumab and pertuzumab may be a useful treatment option for HER2-positive breast cancer, improving time efficiency and patient satisfaction.
- A Rapid Digital Patient-Derived Organoid Guiding Therapy After Antibody Drug Conjugates (ADC)s In Patients with Metastatic Breast Cancer[YY1] [YY1]The size limit (including title and body) is 3,400 characters; this does not include spaces. (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1024;
The DPO platform shows promise in predicting treatment responses and differentiating resistance mechanisms to ADCs in MBC. This approach provides a foundation for rational selection among different ADCs and chemotherapies, especially after acquired resistance to prior ADC treatment, in patients with advanced breast cancer.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Halaven (eribulin mesylate) / Eisai
Evidence Accumulates Against Sequencing Topo1-ADCs in HER2-Low Metastatic Breast Cancers: results from International, retrospective, real-world ADC-Low-Europe cohort. (302 ABC) - Oct 30, 2025 - Abstract #SABCS2025SABCS_766;
We conducted an European, retrospective, real-world study in pts with HER2-low MBC who received Sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd), either sequentially or not...The median progression-free interval (PFI) following ADC1 was 2.9 months [95% CI: 2.7-3.6] in the overall population, 2.7 months [95% CI: 2.5-3.5] with eribulin (n=79) and 4.2 months [95% CI: 2.7-5.7] with capecitabine (n=30).At ADC2 initiation, 81.3%, 7.6% and 22.7% of the pts had visceral, bone-only and brain/meningeal metastases, respectively...These results highlight the need: first to develop biomarkers to better identify pts that could be sensible to a second TOPO1-ADC; second to better select the choice of ADC1 since it has the greatest impact on natural history. About 150 additional pts from French and European centers are currently being enrolled and will be included to the final presentation.
- OTS167 / OncoTherapy, Halaven (eribulin mesylate) / Eisai
Combination of a novel MELK inhibitor with standard of care treatment results in tumor regression and improved survival in a triple-negative inflammatory breast cancer xenograft model. (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_631;
These findings provide a rationale for further investigation into MELK-targeted combination therapies to enhance the efficacy of existing therapies and immune activation in aggressive cancers. We plan to assess the prognostic value of MELK, EMT, and immune markers based on mIF analysis of patient samples.
- Orserdu (elacestrant) / Menarini, Halaven (eribulin mesylate) / Eisai, Truqap (capivasertib) / AstraZeneca
Poor response to systemic therapy upon progression on cyclin dependent kinase 4/6 inhibitors in HR+ Inflammatory Breast Cancer (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_484;
CONCLUSION Patients with metastatic HR+ IBC demonstrate poor response to ET and cytotoxic chemotherapies upon progression on first line standard CDKI/ET, with a disproportionately high rate of death occurring in the first line setting due to advanced disease. Given previously reported low ToT on CDKI/ET in the first line and high incidence of brain relapse in this population, clinical trial design utilizing targeted therapies and more novel approaches in earlier settings are worthy of consideration.
- | NSC305787 / Georgetown University, Halaven (eribulin mesylate) / Eisai, paclitaxel / Generic mfg.
Journal: New molecular targets in acute leukemias: cytoskeletal regulatory proteins. (Pubmed Central) - Oct 29, 2025
This review aims to explore the roles of STMN1 and EZR in the pathogenesis of acute leukemias, assessing their potential as therapeutic targets. The goal is to synthesize recent evidence to guide the development of more effective inhibitors, focusing on overcoming therapeutic resistance and tailoring treatments to individual profiles.
- Ziihera (zanidatamab-hrii) / Jazz
EmpowHER-303: A Phase 3 Study to Evaluate the Efficacy and Safety of Zanidatamab vs Trastuzumab With Chemotherapy in Patients With Metastatic HER2-Positive Breast Cancer Whose Disease Has Progressed on Trastuzumab Deruxtecan (Prince George's Exhibit Hall AB) - Oct 24, 2025 - Abstract #JADPRO2025JADPRO_284;
P3
The goal is to synthesize recent evidence to guide the development of more effective inhibitors, focusing on overcoming therapeutic resistance and tailoring treatments to individual profiles. Background
- | Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Secondary Publication of Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Cutaneous Angiosarcoma 2025. (Pubmed Central) - Oct 16, 2025
Key recommendations include weakly recommending CRT for large (??5?cm) nonmetastatic tumors, preferring drug modification over excision for residual lesions after CRT, and equally considering docetaxel, pazopanib, or eribulin for paclitaxel-resistant cases...Future directions emphasize the need for multicenter registry studies and prospective trials to refine treatment strategies. As advances in genomic medicine and immunotherapy evolve, guideline updates will be essential to ensure optimal patient care.
- || Halaven (eribulin mesylate) / Eisai
Review, Journal, Adverse events: Reporting Matters: Severe Adverse Events in Soft Tissue Sarcoma Therapy-A 30-Year Systematic Review of Placebo- and Non-Systemic-Controlled Randomized Trials. (Pubmed Central) - Oct 16, 2025
Confidence in these estimates is limited by incomplete and non-standardized AE reporting. Future sarcoma trials must adopt CTCAE v5.0, specify explicit safety denominators, and publish full AE matrices to enable high-certainty risk-benefit assessment.
- Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD), farletuzumab ecteribulin (MORAb-202) / Eisai
Open label, multicenter, phase 2 study of farletuzumab ecteribulin (FZEC), a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC), alone and in combination with lenvatinib in platinum-resistant ovarian cancer (PROC) (Level 2' Exhibit Hall D; In-Person Only) - Oct 13, 2025 - Abstract #AACRNCIEORTC2025AACR_NCI_EORTC_530;
Future sarcoma trials must adopt CTCAE v5.0, specify explicit safety denominators, and publish full AE matrices to enable high-certainty risk-benefit assessment. Available on Wednesday, October 22, 2025 at 01:00pm EDT.
- ||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trial completion date: Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] (clinicaltrials.gov) - Oct 6, 2025
P3, N=557, Active, not recruiting, Sponsor: Daiichi Sankyo
Available on Wednesday, October 22, 2025 at 01:00pm EDT. Trial completion date: Oct 2025 --> Aug 2026
- Halaven (eribulin mesylate) / Eisai
Minimal important differences in the EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: Results from a randomized trial (Hall 401) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_1465;
This study identified MIDs for the QLQ-C30 and QLQ-BR23 in Japanese patients with metastatic breast cancer. These findings may help clinicians and researchers in interpreting changes in QOL scores.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, Halaven (eribulin mesylate) / Eisai, Imfinzi (durvalumab) / AstraZeneca
Triple-negative breast cancer with somatic BRCA1 mutation and metaplastic progression in a young woman: A case report (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_1309;
These findings may help clinicians and researchers in interpreting changes in QOL scores. She underwent modified radical mastectomy with sentinel lymph node biopsy, followed by adjuvant doxorubicin
- HydroLock: A versatile ADC platform with robust plasma stability, excellent bystander killing and superior in vivo efficacy (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_363;
All these results warrant HydroLock as a novel and promising linker-payload platform for ADC development. HydroLock was leveraged in several bispecific ADC programs and the first IND submission is expected in late 2025.
- mecbotamab vedotin (BA3011) / BioAtla
Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC. (Poster Hall (Exhibit Halls AB); Virtual) - Oct 3, 2025 - Abstract #SITC2025SITC_859;
The manageable safety profile remained consistent with previous reports. Further evaluation of Mec-V, potentially in novel combinations, is justified.Trial Registration NCT03425279Ethics Approval The study was performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH/GCP.Abstract 523 Table 1View inline
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial: The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis (clinicaltrials.gov) - Oct 3, 2025
P2, N=184, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- ||||||| Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Trial completion date, Trial primary completion date: EMERALD: A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (clinicaltrials.gov) - Sep 29, 2025
P3, N=446, Completed, Sponsor: Japan Breast Cancer Research Group
Further evaluation of Mec-V, potentially in novel combinations, is justified.Trial Registration NCT03425279Ethics Approval The study was performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH/GCP.Abstract 523 Table 1View inline Recruiting --> Completed | Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Apr 2022 --> Dec 2024
- | Halaven (eribulin mesylate) / Eisai
Journal: ERK-driven autophagy enhances synergy of eribulin and cisplatin in triple-negative breast cancer. (Pubmed Central) - Sep 29, 2025
ERK inhibition reversed these effects, confirming its role in mediating synergy. The present findings provide a mechanistic rationale for an affordable combination therapy that may enhance TNBC treatment efficacy, particularly in resource-limited settings.
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma, Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Clinical, P2 data, Journal: Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial). (Pubmed Central) - Sep 24, 2025
The combination of Eribulin and Pyrotinib emerges as a viable treatment option for HER2-positive advanced breast cancer patients who have exhibited resistance to trastuzumab. Despite advancements in anti-HER2 therapies, further research is required to address remaining challenges in this specific clinical scenario.
- ||| JSKN016 / Alphamab
Enrollment open: Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer (clinicaltrials.gov) - Sep 18, 2025
P1/2, N=180, Recruiting, Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Despite advancements in anti-HER2 therapies, further research is required to address remaining challenges in this specific clinical scenario. Not yet recruiting --> Recruiting